title: AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs.
authors.forename: H
authors.initials: H
authors.lastname: Gutgesell
authors.forename: D
authors.initials: D
authors.lastname: Atkins
authors.forename: R
authors.initials: R
authors.lastname: Barst
authors.forename: M
authors.initials: M
authors.lastname: Buck
authors.forename: W
authors.initials: W
authors.lastname: Franklin
authors.forename: R
authors.initials: R
authors.lastname: Humes
authors.forename: R
authors.initials: R
authors.lastname: Ringel
authors.forename: R
authors.initials: R
authors.lastname: Shaddy
authors.forename: K A
authors.initials: KA
authors.lastname: Taubert
mesh_terms: D000293:Adolescent; D002319:Cardiovascular System / Q000187:drug effects*; D002648:Child; D016757:Death, Sudden, Cardiac / Q000517:prevention & control*; D004347:Drug Interactions; D016903:Drug Monitoring; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D011619:Psychotropic Drugs / Q000009:adverse effects* / Q000494:pharmacology
chemical_list: D011619:Psychotropic Drugs